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Abstract: Pharmacological treatment of growth hormone deficiency (GHD) in adults began in clinical
practice more than 20 years ago. Since then, a great volume of experience has been accumulated on its
effects on the symptoms and biochemical alterations that characterize this hormonal deficiency. The
effects on body composition, muscle mass and strength, exercise capacity, glucose and lipid profile,
bone metabolism, and quality of life have been fully demonstrated. The advance of knowledge has
also taken place in the biological and molecular aspects of the action of this hormone in patients
who have completed longitudinal growth. In recent years, several epidemiological studies have
reported interesting information about the long-term effects of GH replacement therapy in regard
to the possible induction of neoplasms and the potential development of diabetes. In addition,
GH hormone receptor polymorphism could potentially influence GH therapy. Long-acting GH are
under development to create a more convenient GH dosing profile, while retaining the excellent
safety, efficacy, and tolerability of daily GH. In this article we compile the most recent data of
GH replacement therapy in adults, as well as the molecular aspects that may condition a different
sensitivity to this treatment.
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1. Introduction
The syndrome of growth hormone deficiency (GHD) in adulthood has been fully defined [1,2] and
is characterized by alterations in body composition, decreased capacity for exercise and quality of life
(QoL), as well as a series of unfavorable changes in cardiovascular function, and lipid and carbohydrate
metabolism. Its diagnosis is based on the combination of pituitary disease, hypopituitarism and a
decrease in the concentration of insulin-like growth factor I (IGF-I) or in diminished GH responses to
different stimuli. A concentration of IGF-I below normal for age and sex in a patient with involvement
of three or more pituitary axes is diagnostic of GHD. Expert consensus defines severe GHD as a GH
response peak after insulin hypoglycemia below 3 µg/L. This is an arbitrary limit that depends on
the assay method, the laboratory, and the type of stimulation. Other stimuli used have been the
GH-releasing hormone (GHRH) plus arginine, GHRH plus GH-releasing peptide (GHRP-6), glucagon,
or the long oral glucose test [3–5].
Replacement therapy with recombinant human GH has been available since the 1980s. The
experience accumulated since then is extensive, and nowadays there is no doubt that this therapy
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improves or reverses most of the signs and symptoms of this hormonal deficiency (Table 1). However,
chronic GH administration is not without potential risks (Table 1).
Table 1. Long-term benefits and risks of growth hormone replacement therapy in adult patients with
growth hormone deficiency.
Patient Data Benefits Risks or Drawbacks
Body composition
Reduction in fat mass
Increase in lean mass
Increase in muscle strength
Increase in BMI
Increased waist circumference
Increase of waist-hip index
Bone metabolism Increase in bone mineral density Effect on the incidence of fractures notclearly shown
Health-related quality
of life
Improvement in quality of life questionnaires
Greater benefit in patients with low quality of
life at baseline
No improvement in all dimensions
Probable absence of effect in patients
with normal quality of life
Cardiovascular risk
markers
Increase in HDL-chol
Reduction of total and LDL-chol
Diastolic blood pressure reduction
Reduction of CRP
Reduction of carotid intima-media thickness
Reduced insulin sensitivity
Increase in fasting glucose and insulin
Trend to the increase in the prevalence
of metabolic syndrome
Increase in lipoprotein (a)
Cardiovascular disease Reduction in the incidence rate ofmyocardial infarction
Trend to increase in
cerebrovascular disease
Neoplasms
No increase in the rate of recurrence or
progression of hypothalamic-pituitary tumors
No increase in overall risk of neoplasia in
adults with GHD
Tendency to increase risk of second
malignancy in childhood cancer
survivors treated with GH
in childhood
There are subgroups with increased
risk of certain neoplasia in adults who
were treated with GH in childhood
Mortality Tendency to decrease the global andcardiovascular mortality of hypopituitarism
Persistence of higher mortality than
the general population in
some studies
Abbreviations: BMI, body mass index; chol, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein;
CRP, C-reactive protein; GHD, deficiency of growth hormone.
We herein review the most recent data and summarize our current knowledge about the benefits
and risks of GH replacement therapy in adults deficient in this hormone. All articles related to
replacement therapy of growth hormone deficiency were searched in MEDLINE from 1985 to 2017.
The search was performed by using the terms “replacement therapy” and “adult” as subheadings of
the term “growth hormone deficiency” in the Medical Subject Headings (MeSH) thesaurus. All clinical
trials and systematic reviews related to growth hormone deficiency were also searched at the Cochrane
Database of systematic Reviews and The Cochrane Central Register of Controlled Trials (CENTRAL).
The selection criteria included all prospective and retrospective studies, all case series, all case reports,
and reviews concerning the effects of growth hormone replacement therapy on adult patients with
GHD. Duplicated articles were excluded. This search was supplemented by a review of reference lists
of potentially eligible studies and a manual search of key journals in the field of endocrinology.
2. Benefits of Treatment with Growth Hormone
GH replacement therapy is associated with beneficial effects on body composition, bone structure,
health-related QoL and several cardiovascular risk factors [6,7].
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2.1. Body Composition
Initial studies showed that treatment with GH induced a decrease in fat mass and an increase in
lean mass [8]. Elbornsson et al. [9] in a cohort of 156 patients with GHD, reported an improvement in
lean mass maintained for 15 years, and a marked initial decrease in fat mass, followed by a slowly
progressive increase over time, in possible relation with the aging process. A recent systematic review
concluded that the long-term effects on body mass index appear to be inconclusive, with some studies
reporting an increase and other reporting no change [7]. On the other hand, most long-term studies
report no effect of GH replacement therapy on waist-hip ratio or waist circumference. A slight but
significant increase in waist circumference has been reported in one study [10]. It has been postulated
that the observed increase in body mass index and waist circumference in some studies is in line with
changes due to normal aging process [11,12]. In other words, it is possible that in long-term studies
the aging process attenuates some of the beneficial effects of GH treatment on body composition.
Interestingly, data from the study by Filipsson Nystrom et al. [13] showed that discontinuation of
GH therapy for four months, after more than three years of treatment, was followed by an increase in
abdominal subcutaneous and visceral fat and a decrease in thigh muscle mass. A recent meta-analysis
of 22 trials, including 591 GH- and 562 placebo-treated patients, found that mean lean body mass
increased by 2.61 kg in GH-treated subjects versus 0.04 in the placebo group, and that fat mass was
reduced by 2.19 kg versus 0.31 (GH vs. placebo). Changes in lean body mass and fat mass were
dose-related, with high dose (HD) being more effective than low dose [14].
Lean body mass, including both skeletal muscle mass and tissue hydration, is increased with
GH replacement therapy [15]. GH therapy causes an increase in the tubular reabsorption of sodium
in the distal nephron. This is accompanied by an increase in plasma renin activity and decreased
brain natriuretic peptide levels [16]. In addition, although treatment with GH is accompanied by an
increase in lean body mass, most studies do not allow differentiating between extracellular water and
intracellular mass [7]. Therefore, the lean body mass data may not be accurate, as GH replacement is
associated with an increase in the intracellular water component. However, GH replacement therapy
increases muscle strength and exercise capacity in patients with GH deficiency. In the study by
Gotherstrom, GH treatment during 10 years in patients with GHD increased muscle strength during
the first half of the study and later protected from the decline in muscular strength that occurs with
aging [17]. These data, although indirectly, clearly suggest a real increase in muscle mass.
2.2. Bone Structure
Replacement therapy with GH in adult patients with GHD increases bone mineral density (BMD)
and helps to optimize peak bone acquisition in patients who have persistent GH deficiency during the
transition from adolescence to adulthood [6,7,18].
The effect on BMD is greater at vertebral than femoral level and after 18–24 months of treatment,
and most studies show an increase of 4–10% of BMD [19]. In patients with childhood-onset GHD it has
been shown that the continuation or reinstitution of treatment for two years, in patients who completed
growth, induced a significant increase in BMD compared to untreated patients [20]. Therefore,
the continuation of GH treatment during the period of transition from childhood to adulthood is
recommended to obtain complete bone maturation. A prospective study in 18 patients with GHD
showed that seven years of GH treatment induced an increase in lumbar spine BMD, which stabilizes
during long-term therapy. However, a significant positive effect on bone microarchitecture could
not be demonstrated in these patients [21]. Furthermore, two recent meta-analyses have suggested
that the beneficial effect of GH therapy on BMD in adults with GHD is mainly affected by gender,
age, dose and treatment duration [22,23]. In a cohort of 230 adult GHD patients, followed up to
15 years, Appelman-Dijkstra et al. [24] demonstrated a sustained increase in BMD at the lumbar spine,
particularly in men, and stabilization of BMD values at the femoral neck. This study suggested that
the clinical fractures incidence was no increased during long-term GH replacement [24].
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Estrogenic hormonal status exerts also influence on the GH replacement therapy effects on bone
metabolism. In a prospective, single-center study, including 87 consecutive patients (52 men and
35 women) with adulthood onset GHD, GH replacement induced a sustained increase in total, lumbar
and femoral neck BMD and bone mineral content. There was a tendency for women on estrogen
treatment to have a greater increase in bone mass and density compared with women without estrogen
replacement. This study suggests that adequate estrogen replacement is needed in order to have an
optimal response in bone mineral density in GHD women [25].
2.3. Quality of Life
GH treatment improves health-related QoL in the majority of patients. Most of the improvement
in QoL occurs during the first year of treatment, although this beneficial effect persists in the medium
and long term [26]. Sustained improvement in QoL scores has been shown to be more marked in
women and in patients with low QoL at baseline [27,28].
A special group consists of patients with a previous history of acromegaly who subsequently
presents GHD. This particular group of patients exhibits a significant deterioration of health-related
QoL that is improved by GH replacement [29].
2.4. Cardiovascular Risk Markers
Treatment with GH in patients with GHD improves several cardiovascular risk factors, such as
lipid profile, endothelial function and cardiovascular inflammatory markers [30,31].
Dyslipidemia has been considered the strongest contributor of the excess in cardiovascular risk
associated with hypopituitarism [31]. Most studies have shown an increase in high-density lipoprotein
(HDL) cholesterol and a decrease in total cholesterol and low-density lipoprotein (LDL) cholesterol
after administration of GH [32]. Withdrawal of GH treatment for four months, after more than three
years of administration, was accompanied by an increase in total and LDL cholesterol [13], which
indirectly shows one of the great benefits of the GH therapy in patients with GHD. The positive
effect of GH therapy on lipid profile has been confirmed in a long-term 15-year prospective study [9].
Furthermore, a slight decrease in diastolic blood pressure has been demonstrated in a meta-analysis
of placebo-controlled studies [33]. Inflammatory markers are elevated in patients with GHD and
treatment with GH can improve low-grade inflammation, as documented by a reduction in C-reactive
protein, TNF-α, and interleukin-6 [13,31,34].
Increased thickness of the carotid intima-media is an important predictor of coronary disease in
epidemiological studies. Replacement with GH in patients with GHD has been shown to decrease this
parameter [35]. The study by Makimura et al. [36] is of particular interest in this context. In patients
with obesity and decreased GH secretion, randomized and placebo-controlled administration of a
GHRH analogue induced a decrease in visceral fat mass and in the intima-media thickness of the
carotid, in addition to a moderate elevation of IGF-I [36].
2.5. Influence of Severity
Patients who are most likely to benefit from GH replacement therapy include those with severe
GH deficiency, defined by the response to GH provocative testing and serum IGF-1 levels, including
patients with genetic and other congenital causes of GH deficiency. Retesting during the transition
to adulthood in children with idiopathic GH deficiency is necessary but is not mandatory in patients
expected to have lifelong severe GH deficiency owing to causes such as genetic mutations, structural
lesions, or deficiencies of multiple pituitary hormones. In addition, continued GH replacement therapy
during the transition period after completion of linear growth is recommended to permit achievement
of full skeletal and muscle maturation [15].
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2.6. Influence of Age
The patient’s age should be taken into account when considering GH replacement therapy.
GH secretion normally decreases with age, and older patients have an increased susceptibility to
GH-related side effects. Therefore, GH dose requirements are lower in older patients and higher in
some transition and young adult patients [20], especially if serum IGF-I are very low [37]. On the
other hand, there are no well-conducted prospective studies on the effect of age on the benefits and
risks of GH replacement. In a systematic review of eleven studies in patients older than 60, treatment
with GH decreased total and low density lipoprotein cholesterol levels, but did not alter high density
lipoprotein or triglyceride levels. In addition, GH did not affect body mass index, blood pressure, or
bone mineral density but decreased waist circumference, increased lean body mass, and decreased
total fat mass. GH replacement consistently improved QoL.
There are no data on the efficacy and safety of GH treatment in patients older than eighty years [38].
In a prospective, single-center, open-label study, the effects of GH replacement were determined in
24 GHD adults above 65 years of age and in 24 younger GHD patients. Despite the lower dose in the
elderly group, these patients had a more marked reduction in waist/hip ratio and serum low-density
lipoprotein-cholesterol level, and these differences remained also after correction for duration of
hypopituitarism. There was no difference at baseline or in responsiveness in lean mass, bone mineral
density, and glucose homeostasis [39].
2.7. Other Beneficial Effects
Sleep disturbances have been reported in patients with GHD. Morselli et al. [40] have shown that
four months of GH replacement therapy partly reversed sleep disturbances previously observed in
untreated patients [40]. Cardiac size and cardiac performance have been reported to improve with GH
replacement therapy [34]. A prospective study in 14 patients with adult-onset GHD showed that one
year of GH therapy improves coronary flow reserve and left ventricular diastolic function in the patient
population analyzed, thereby encouraging the early start of GH replacement therapy [41]. Six months
of GH treatment significantly improved anaerobic capacity and physical function in a time-dependent
manner in adults with GHD [42].
Retrospective [43,44] and prospective [45] studies have shown that patients with hypopituitarism
treated with usual replacement therapy without GH exhibit an increased mortality in comparison
with general population, especially concerning CV disease. In a group of 1411 hypopituitary adults
without GH replacement, Svensson et al. [44] found that overall mortality and the rates of myocardial
infarctions, cerebrovascular events, and malignancies were increased compared with the normal
population. In a cohort of 289 patients on GH replacement, overall mortality and the rate of
malignancies were similar to the normal population. The rate of myocardial infarctions was lower
than that in the background population, although there was a tendency toward an increased rate of
cerebrovascular events in this cohort. Therefore, it has been suggested that GH replacement appeared
to provide protection from myocardial infarctions [44].
3. Risks of GH Replacement Therapy
3.1. Body Composition
Not all GH-induced changes in body composition are favorable. The waist circumference and
the body mass index (BMI) increase significantly in some studies [46]. A systematic review of
23 prospective studies of GH treatment for 5–15 years showed an increase in BMI, waist circumference
and waist-hip index. In addition, although treatment with GH is accompanied by an increase in lean
body mass, most studies do not allow differentiating between extracellular water and intracellular
mass [7].
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3.2. Bone Structure
Childhood-onset GHD is associated with a reduction in bone mass, but this is not the case in
adult-onset GHD [47,48]. Best responses are seen in men and in patients with lower BMD at the
beginning of treatment. However, studies do not detail the use of calcium, vitamin D or antiresorptive
drugs [7], being difficult to draw conclusions. In addition, to date, no randomized controlled study
has shown effects of GH treatment on the rate of fractures.
3.3. Quality of Life
A recent retrospective analysis of patients who were treated with GH during childhood in
11 centers of pediatric endocrinology in Switzerland compiled the information on QoL during adult
life. Data of 300 participants showed that QoL results are in relation with the underlying indication for
GH treatment. In particular, patients with associated diseases or syndromes scored slightly lower, and
former cancer patients scored lower than patients with isolated GHD or idiopathic short stature. Lower
physical component summary was associated with lower educational level [49]. These data emphasize
the need to bear in mind the underlying condition when interpreting results of QoL measurements in
adults with childhood onset GHD.
QoL improvements have not been reported in all adults or in all assessed socio-psychological
domains [50,51]. Some studies have shown even worsening in some domains, such as social
function and mental health, in adults with childhood-onset GHD [52]. In general, responses are
very heterogeneous and patients with worse QoL before treatment are the best responders [27,28].
Therefore, it is possible that patients who have a normal QoL at baseline do not benefit from GH
treatment in this regard.
3.4. Cardiovascular Risk Markers
Some authors have shown that lipoprotein (a), an independent marker of cardiovascular risk,
increases significantly during treatment with GH [53]. In addition, one study has observed an increase
in atherosclerosis plaques after six months of GH replacement therapy in adults with previously
untreated congenital GHD due to mutation of the GHRH receptor [54].
3.5. Adverse Events
Side effects derived from water retention caused by GH occur in 5–18% of patients. They are
edema, arthralgias, myalgias, paresthesias, and carpal tunnel syndrome, and usually improve after
dose reduction. Elderly, female, and overweight patients have a higher risk of developing these effects.
Retinopathy and benign intracranial hypertension are very rare complications of GH treatment. The
needs of cortisol and thyroxin may be increased in patients with hypopituitarism [55]. Special attention
should be given to older, heavier, and female patients with GHD because they are more susceptible
to adverse events. Monitoring IGF-I concentrations is essential to avoid adverse effects of excess GH
treatment. A recent randomized, open-label, clinical trial including 32 adults receiving GH therapy
for at least one year showed that although increasing GH dose to achieve IGF-I levels between 1
and 2 Standard Deviation Score (SDS) improved waist circumference and the overall better feeling,
safety was not guaranteed with the demonstrated effect on HDL cholesterol in men, and reported
myalgia [56].
To minimize the impact of adverse effects, it is appropriate to start treatment with low doses
and titrate upwards according to clinical response and IGF-I levels, as well as following some general
recommendations that are shown in Table 2.
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Table 2. General recommendations for the treatment with GH in adults with GHD.
No. Steps
1 Start GH replacement therapy only in adult patients with severe GHD fullydemonstrated with adequate diagnostic tests
2 Use the minimum effective dose in each patient, starting with low doses
3 Use lower starting doses in the elderly and diabetics
4 Adhere the recommendations of the national and international guidelines for thefollow-up of adult patients with GHD
5 Avoid IGF-I concentrations above the upper limit of normal range for the age andsex of the patient
6 Monitor blood glucose, hemoglobin A1c and lipid profile periodically and afterchanging doses
7 In patients with a prior history of tumors of the hypothalamus-pituitary areaevaluate magnetic resonance imaging of the pituitary gland
8 Monitor the occurrence of adverse effects and inform the health authority
3.6. Risk of Hyperglycemia and Diabetes
Treatment with GH reduces insulin sensitivity and elevates blood glucose. In one study, conducted
in 90 patients on GH treatment, a significant increase in both glucose and hemoglobin A1c levels was
demonstrated. Changes were evident at six months and persisted after two years of treatment [57].
These data have been corroborated in some studies [58] and by a meta-analysis of 37 randomized,
placebo-controlled, clinical trials, which showed that GH treatment was accompanied by an increase in
fasting blood glucose and insulin concentrations, regardless of the dose and duration of treatment [33].
In a randomized, double-blind, placebo-controlled clinical trial in 166 adult patients with GHD,
treatment with GH was associated with a worsening of glucose tolerance with the appearance of
diabetes in 4% and carbohydrate intolerance in 20% of patients after 12 months, while in the placebo
group only 8% developed intolerance [32].
In the Hypopituitary Control and Complications Study (HypoCCS) the prevalence and incidence
of diabetes in adults treated with GH has also been analyzed [59]. Results of an analysis of 2922 patients
in the United States and 3709 in Europe, with a mean follow-up of 4.1 years, showed that, in the
United States, the incidence rate of diabetes adjusted for age, sex, and BMI is higher in patients
treated with GH than in the general population. In France and Germany, the incidence rates were
comparable with the reference population, while in Sweden the incidence rate was more than double
in patients on GH treatment. A more recent analysis of 5143 patients from the Pfizer International
Metabolic Database (KIMS), with 20,106 patient-year follow-up showed that, in southern Sweden, the
observed/expected cases ratio was 10.8 the first year of treatment with GH and fell to 1.9 after eight
years of treatment, but always stayed above 1. When the incidence of diabetes in patients in the KIMS
study was compared with the incidence rates in age-adjusted populations in other European and US
regions, the observed/expected cases ratios ranged from 2.11 to 5.22 [60].
The Safety and Appropriateness of Growth Hormone Treatment in Europe (SAGhE) was a
population-based cohort study that analyzed the long-term mortality and morbidity in adults who were
treated with GH during childhood. A recent report by Poidvin et al. [61] have used the French SAGhE
database to evaluate the prevalence of diabetes, including gestational diabetes, in a population-based
cohort of patients treated with GH for short stature during childhood, and to compare this prevalence
with that of the general population in France. They analyzed a cohort of 5100 children with idiopathic
short stature, or short stature in children born short for gestational age. In summary, these authors
found no increase in the risk of treated diabetes in subjects receiving GH treatment during childhood,
with a mean follow-up of 19 years.
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A recent study in 245 patients with adult-onset GHD and more than four years of GH replacement
showed that this therapy did no adversely affect glucose homeostasis in the majority of adults patients,
although seven patients developed diabetes [62]. A meta-analysis of 94 randomized controlled trials
and open trials did not demonstrate neither an increased frequency of diabetes in the short-term placebo
controlled trials or a consistently increased incidence of diabetes during long-term GH replacement.
However, the small number of subjects and the absence of adequate control population are a limitation
for the interpretation of these results [63].
Close monitoring of glucose status is advisable during GH treatment in patients with obesity or a
family history of type 2 diabetes, because they are more prone to develop impaired glucose intolerance
and diabetes during therapy [64].
3.7. Risk of Neoplasia
Epidemiological studies have suggested an association of high circulating IGF-I or GH to
cancer incidence [65,66], and the incidence of some malignant neoplasia is known to be increased in
acromegaly [67]. Initial studies conducted in children treated with extractive GH showed an increased
risk of mortality from cancer and, in particular, from colorectal cancer and Hodgkin’s disease [68].
The oncogenic risk during treatment in children treated with GH was established in the National
Cooperative Growth Study (NGCS) and the Pfizer International Growth Database (KIGS), which
evaluated more than 50,000 patients each, with almost 200,000 patient-years each. The standardized
incidence rate of cancer was 1.12 (95% confidence interval: 0.75–1.61) in the former [69] and 1.26
(0.86–1.78) in the latter [70], thus suggesting that there was no significant increase in the risk of cancer
in these children. No greater risk of leukemia than the general population could be demonstrated
in these studies. Furthermore, recent studies have not confirmed an increased risk of mortality in
children treated with GH, especially when applying sex-specific mortality models adjusting for birth
characteristics [71].
The risk of second neoplasia in survivors of childhood cancer has been analyzed in depth in the
Childhood Cancer Survivor Study (CCSS). In a scrutiny conducted in 2002, this study showed that
children treated with GH had a relative risk for cancer of 3.21 (1.88–5.46) in comparison to cancer
survivors not treated with this hormone [72]. This relative risk was even higher, 4.98 (1.95–12.74),
in leukemia survivors. In the 2006 analysis [73], including a further 32-month follow-up, the risk of
second neoplasia was reduced to 2.15 (1.33–3.47), but remained significant. Another study in one
center, including 49 patients with GHD within a cohort of 310 childhood cancer survivors, showed
that GH replacement therapy did not seem to increase the risk of second neoplasia, but the authors
suggest the need of a close long-term follow-up in these patients [74].
Data available in adult patients suggest that replacement therapy with GH does not increase the
rate of recurrence or progression of tumors in the hypothalamic-pituitary area [75].
An analysis of the risk of neoplasia was carried out in the SAGhE study database, including
6928 patients treated for idiopathic GHD, neurosecretory dysfunction, idiopathic short stature and
small for gestational age, that is, etiologies of GHD without increased risk of neoplasia. Mean time
of follow-up after completing therapy was 7.8 years [76]. In this study, the standardized mortality
ratio for bone and cartilage neoplasia reached the striking figure of 5.00 (1.01–14.61). In a group of
6840 adults included in the HypoCCS study, the incidence ratio of neoplasia was 0.88 (0.74–1.04), but it
rose to 3.79 (1.39–8.26) when patients younger than 35 years were analyzed, and to 2.74 (1.18–5.42)
when analyzing patients with childhood onset GHD [77]. These results suggested that the overall risk
of primary cancer in adult life is not increased; however, there are subgroups with high risk.
Using the HypoCCS database, Child et al. [78] reported the incidence of primary neoplasia in a
cohort of 8418 patients treated with GH, as well as in 3668 GH-treated patients with history of pituitary
adenoma and 956 GH-treated patients with history of craniopharyngiomas. Comparison were carried
out with cohorts of untreated patients. During a mean follow-up of 4.8 years, they found that no
increased risk for all-site cancers, including breast, prostate and colorectal cancers, in GH-treated
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patients. In addition, GH treatment did not increase the risk of recurrence of pituitary adenoma or
craniopharyngioma in this study.
Recent studies have also reported reassuring results. A recent study, including 426 patients with
nonfunctioning pituitary adenomas, with 4599 patient-years of follow-up, of whom 207 had used GH
therapy and 219 had not received GH, showed a reduced overall mortality in GH-treated patients
compared with the general population and found that death due to malignancy was not increased in
GH-treated patients [79]. However, selection bias explaining some of the results cannot be excluded in
this study. On the other hand, a recent metaanalysis, including two retrospective and seven prospective
studies with a total of 11,191 participants, suggested that GH replacement therapy could reduce risk of
cancer in adult with GHD [80].
Nevertheless, GH therapy should not be given to patients with active malignancy [64], and should
be prescribed with caution in GHD adult patients with a history of cancer, strong family history of
cancer, and advancing age [81,82]. Childhood cancer survivors may be at increased risk for secondary
neoplasm compared with general population. GH should be used cautiously in this subgroup of
patients [81].
3.8. Mortality Risk
A study conducted with data from the Dutch National Registry of GH treatment [83] compared
2229 patients undergoing treatment with GH with a primary control group of 109 patients diagnosed
but not treated with GH and a secondary control group of 356 patients treated with GH in whom
the treatment had been discontinued. The standardized mortality ratio in relation to the general
population was 1.27 (1.04–1.56) for the treatment group. This ratio was 1.29 (1.05–1.59) when patients
with acromegaly and Cushing’s disease were excluded, and 1.00 (0.79–1.26) after the exclusion of
high-risk patients (craniopharyngioma and other causes). It is noteworthy that the authors found
no significant increase in mortality in the two untreated control groups. The authors also found a
significant increase in the standardized mortality ratio due to cardiovascular disease in women in the
treatment group (2.52 [1.57–4.06]), which persisted after exclusion of high-risk patients.
The evaluation of a group of 13,983 GH-treated patients, with a mean follow-up of 4.9 years,
showed that all-cause mortality in these patients was 13% higher than in the general population
(standardized mortality ratio of 1.13 [1.04–1.24]). There was no increase in mortality due to
cardiovascular disease or cancer [84]. In the aforementioned SAGhE study, the risk of overall mortality
in patients who received GH in childhood increased by 33%. In this study, the standardized mortality
ratio for circulatory diseases was 3.07 (1.40–5.83), and rose to 5.29 (1.42–13.55) and 6.66 (1.79–17.05)
when deaths due to cerebrovascular disease and intracranial hemorrhage were considered, respectively.
On the contrary, the observational GeNeSIS study, evaluating 9504 GH-treated children followed
for at least four years found no increase in risk of mortality compared with children in the general
population [85]. This study found an increase in mortality risk for children with history of malignant
neoplasia. However, this study is limited to the period of active treatment with GH and without
follow-up in adult life.
In summary, as stated in the Endocrine Society clinical practice guideline [6], although mortality
is increased in patients with hypopituitarism and GHD has been implicated in this, there is no data to
show that treatment with GH improves the survival of patients.
4. Cellular and Molecular Conditionings of GH Therapy
GH initiates it action by binding to growth hormone receptors (GHR) present on the plasma
membrane of target cells. GHRs belong to the class I cytokine receptor family along with prolactin,
erythropoietin, leptin and interleukins receptor [86,87]. The GHR receptor polymorphism has been
extensively studied [88]. The GHR is a membrane receptor composed of 638 amino acids with three
cellular domains: an extracellular, a transmembrane and an intracellular domain. The extracellular
domain attaches to the circulating GH and corresponds to the circulating GH binding protein [89].
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Activation of the receptor is induced through the interaction of GH to a preformed GHR dimer,
leading to a conformational change in the intracellular domain that results in the phosphorylation and
activation of STAT5 through Janus Kinase 2 [90–92].
The human GHR gene is located in chromosome 5, the mouse GHR gene is located on
chromosome 15 [93,94]. In the human gene there are nine exons that encode the receptor and several
additional exons in the 5′ untranslated region. The coding exons span at least 87 kilobase pairs of
chromosome 5. There are two major isoforms of the GHR that differ by the absence of exon 3 that
encodes part of the extracellular domain of the GHR. Its absence gives rise to a GHR lacking 22 amino
acids in the extracellular domain [93,94]. The first studies of GHR with variations in the coding region
came from the work of Godowski et al. [94] on Laron syndrome, an autosomal recessive genetic
disorder that is characterized by resistance to GH. The isoform of human GHR containing exon 3 is
known as the full-length isoform (fl-GHR) and the isoform without exon 3 as the exon 3-deficient
isoform (d3-GHR). This polymorphism has been extensively studied since the loss of a complete exon
from a gene without affecting the function of the resulting protein is very uncommon. The binding
capabilities of the two GHR isoforms are considered similar [95–97]. The d3-GHR isoform is dominant
over the fl-GHR isoform and about 50% of Europeans are hetero- or homozygous with respect to
the allele encoding the d3-GHR isoform [98]. Dos Santos et al. [98] through transfection experiments
demonstrated that the transduction of GH signaling through d3-GHR homo- or heterodimers was
approximately 30% greater than through fl-GHR homodimers.
Different studies have suggested that GHR polymorphism could influence GHD in adult clinical
presentation and GH responsiveness. For example, vertebral fracture risk has been found decreased in
adult GHD d3-GHR carriers, both in GH treated and untreated patients [99]. Glad et al. observed that
adults with GHD ad fl/fl-GHR genotype showed a better IGF-I response than patients with the d3-GHR
genotype, after one week of GH replacement [100]. Similar results were obtained by Moyes et al.
that studied adult GHD patients after 12 months of treatment, the increase in IGF-I was significantly
greater in the d3/d3 group. No difference in IGF-I increase was detected between fl/d3 and fl/fl
groups and no difference in maintenance GH dose was found between different group genotypes [101].
Meyer et al. evaluated a group of adult patients with GHD derived from the prospective German
Pfizer International Metabolic Study (KIMS) Pharmacogenetics Study. After one year of GH treatment,
the required GH dose was lower in patients carrying one or two d3 alleles, compared with patients
with the fl/fl genotype and there was no significant differences in IGF-I serum concentrations [102].
However there are other experiments with different response patterns. A group of adult GHD
patients divided in two groups have been investigated after one year of GH replacement, 72 patients
had fl/fl genotype, whereas 52 had at least one d3-GHR allele. Baseline values and changes in IGF-I
and body fat after 12 months of GH treatment did not differ between the two genotype groups [103].
Similar results were obtained by Andujar-Plata et al. which could not find any association between
the d3-GHR allele and IGF-I, the incidence of adverse events or treatment discontinuation in a group
of adult-onset GHD patients [104]. In the study of Adetunji et al. the presence of the d3-GHR allele
in adults with GHD did not influence the symptoms of the disease [105]. In another investigation by
the same group it has been found there was no difference in the GH dose required to optimize serum
IGF-I, quality of life or body composition between adult GHD carriers and non-carriers of the d3-GHR
allele [106].
Another group of experiments studied the impact of the d3-GHR polymorphism on the
therapeutic effect of GH replacement in longer term. Van der Klaauw et al. studied adult GHD
patients (56% fl/fl, 44% d3/fl or d3/d3 GHR) after one or five years of GH replacement treatment.
During one year of GH treatment, the increase in IGF-I was higher in carriers of the d3-GHR allele,
compared with the fl/fl-GHR genotype. The decrease in total cholesterol (chol) and low-density
lipoprotein chol was lower in the group with at least one d3-GHR allele, whereas the increase in
high-density lipoprotein chol was higher, compared with non-carriers of the d3GHR allele. These
differential responses of GHR genotype were no longer observed after five years of GH treatment [107].
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Giavoli et al. studied prospectively adult GHD patients (48% fl/fl, 52% d3/fl or d3/d3 GHR) before
and after one or five years GH replacement [96]. GH treatment normalizes IGF-I and decrease the
percentage body fat both at one and five years regardless of the presence of the d3-GHR allele.
At one year, an increase in high-density lipoprotein chol occurred in the d3GHR carriers compared to
non-carriers. After both one and five years, the percentage of subjects with impaired glucose tolerance,
that was similar in the two groups at baseline, decreased in non-carriers and doubled in d3-GHR allele
carriers. In the group of d3-GHR carriers, a five year reduction in total and low-density lipoprotein
chol was observed [108]. Interestingly, the d3-GHR has been found to be a marker of longevity in
males, associated with increased GH sensitivity and tall stature [109].
Taking into account the studies published to date, there is little evidence that GHR polymorphism
have an important impact in the clinical manifestations of the syndrome of adult GHD. The importance
of the d3-GHR variant on the response of adult GHD patients to GH replacement is unclear at the
present time [88,110].
5. Conclusions and Future Research
GH replacement exerts unquestionable beneficial effects in many patients with GHD, and its use
is safe for approved indications [64]. It is necessary to identify potential candidates for treatment and
confirm the GHD before the start of treatment. GH has shown beneficial effects on body composition,
exercise capacity, bone structure, serum lipids, and quality of life (Table 1). The dose should be carefully
individualized, to avoid side effects and adequate periodic monitoring, as is necessary (Table 2). It has
not been shown that GH treatment improves overall mortality, bone fractures, clinical heart disease,
or cancer.
Results of reported studies should be interpreted with caution, including those from large
international databases, since all of them have methodological deficiencies, and must be assessed
with carefulness and critical thinking (Table 3). Nevertheless, although our knowledge about GH
replacement therapy is still imperfect, recent studies that we have commented in this review allow us
to give answers based on scientific evidence to some questions of clinical relevance (Table 4).
Table 3. Critical evaluation of studies on benefits and risks of GH treatment in adult patients.
No. Steps
1 Many studies lack a control group of patients with GHD without GH treatment
2 There are no long-term, placebo-controlled studies
3 There are confounding factors that influence the results such as radiation, chemotherapy,immunosuppression, congenital diseases
4 Concomitant treatments are not always referred in the studies
5 In the long-term results we must consider the effect of age and hypopituitarism
6 In some studies follow-up is short to reach conclusive results on cardiovascular disease,neoplasia or mortality
7 Exposure to GH very variable in the patients included
8 Not all patients exposed to GH are captured in post-marketing studies
9 The studies are very heterogeneous and the designs are very disparate
10 Exposure to GH during childhood can have different effects than exposure during adult life
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Table 4. Questions and answers about GH replacement therapy in adults with GHD.
Question Best Available Response
Does treatment with GH improve the quality
of life of patients? Yes, in most studies
Is an improvement in body composition
achieved?
Yes, it reduces fat mass and increases lean mass.
In the long term too
Does treatment with GH decrease
cardiovascular risk?
Yes, most cardiovascular risk markers experience a
favorable change
Is the fracture rate reduced by
long-term treatment? It has not been proven
Does GH treatment modify blood glucose?
Yes, in the long term blood glucose levels rise and in
some cases the incidence of glucose intolerance and
diabetes increases
Does treatment during adult life increase the
risk of cancer?
Probably not, but there are data that indicate that
there are subgroups with higher risk of neoplasia
Does treatment with GH decrease the
mortality associated with hypopituitarism?
It has not been clearly demonstrated. In adult
patients treated with GH, an increase in mortality
persists, in most studies
There are ongoing preparations of prolonged-release GH, which would reduce the frequency
of injections [111,112]. Nowadays, there are long-acting GH preparations in various stages of
development, including depot, pegylated, and prodrug formulations, as well as non-covalent
albumin-binding GH and GH-fusion protein compounds [113–116].
If its efficacy and safety are confirmed, this type of posology modification would be especially
welcome in clinical practice. One of the main safety concerns of these preparations is the maintenance of
supraphysiological elevations of GH or IGF-I levels, and non-physiological tissue distribution [113,115].
The possibility of modifications in the GH molecule that increase its beneficial effects and decrease its
side effects is a promising way of future research. The long-term safety of GH treatment is an obligation
of health professionals, the pharmaceutical industry and health authorities. Periodic monitoring of
both benefits and adverse effects is necessary. Long-term studies with relevant outcome variables such
as incidence of fractures, cardiovascular disease, cancer, or mortality remain necessary.
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